643 filings
Page 2 of 33
8-K
onkqect
6 Sep 23
Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
4:43pm
8-K
zs2djiaiqs6 wxc
3 Aug 23
Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results
4:20pm
8-K
aiiklmo2kf83bpo0ii
26 Jul 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:20pm
8-K
mt8l sq308oj
10 Jul 23
Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate
4:12pm
8-K
3jzgtykq9whhduovmr4c
28 Jun 23
Submission of Matters to a Vote of Security Holders
4:22pm
DEFA14A
tmnnl
21 Jun 23
Additional proxy soliciting materials
5:18pm
8-K
ruxul319
8 Jun 23
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
4:27pm
424B5
jdhj9g
8 Jun 23
Prospectus supplement for primary offering
4:17pm
424B5
4dbb90dfdnitk
6 Jun 23
Prospectus supplement for primary offering
5:21pm
8-K
1vmvwbp iiid
6 Jun 23
No Vaccine Related Serious Adverse Events (SAEs) reported to date
8:07am
8-K
t3g5e dhcp
25 May 23
Other Events
4:31pm
8-K
fyzdfz8mv5rhtjqu
9 May 23
Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results
4:57pm
424B5
6r5 ya1h55g2te0pac9f
9 May 23
Prospectus supplement for primary offering
2:41pm
EFFECT
ymhpktkvvm9i8ru
8 May 23
Notice of effectiveness
12:15am
CORRESP
teh 2vlmx8
3 May 23
Correspondence with SEC
12:00am
DEFA14A
xshv q6xg
28 Apr 23
Additional proxy soliciting materials
4:21pm
8-K
q6ptpn4nc qo6
31 Mar 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:30am